Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death.

CD95/CD95L interactions are vital to normal lymphoid homeostasis and in the protection against autoimmunity. To directly assess the effects of CD95L on activated B cell survival and Ig responses, purified human peripheral blood B cells, activated in vitro with SAC + rIL2, were incubated with a soluble CD95L fusion protein (fp) and assayed for apoptosis and IgG/IgM production. CD95L fp reproducibly increased apoptosis of these activated B cells and inhibited their Ig production. However, CD95L fp-mediated effects on activated B cell survival could be uncoupled from those on Ig production in that a soluble CD40L fp was incapable of reversing CD95L fp-mediated downregulation of Ig responses despite inhibiting CD95L fp-mediated apoptosis. Moreover, despite the specific caspase-8 inhibitor z-IETD-fmk substantially protecting transformed CL-01 B cells from CD95L fp-mediated apoptosis and permitting their ongoing proliferation, caspase-8 inhibition had no protective effects on CD95L fp-mediated inhibition of constitutive IgM production by CL-01 B cells. Collectively, these results point to a CD95-based downregulatory pathway in activated B cells that need not necessarily culminate in their death.

[1]  C. Bortner,et al.  Caspase Independent/Dependent Regulation of K+, Cell Shrinkage, and Mitochondrial Membrane Potential during Lymphocyte Apoptosis* , 1999, The Journal of Biological Chemistry.

[2]  T. Sumida,et al.  Tumor necrosis factor alpha regulation of the FAS-mediated apoptosis-signaling pathway in synovial cells. , 1999, Arthritis and rheumatism.

[3]  P. Kiener,et al.  Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells. , 1998, Journal of immunology.

[4]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[5]  T. Whiteside,et al.  Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. , 1998, The Journal of clinical investigation.

[6]  P. Kiener,et al.  CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses. , 1998, Journal of immunology.

[7]  T. Giese,et al.  Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions , 1998, The Journal of experimental medicine.

[8]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[9]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[10]  G. Nolan,et al.  Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. , 1998, Immunity.

[11]  N. Harindranath,et al.  CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. , 1998, Journal of immunology.

[12]  T. Ochi,et al.  Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing , 1997, The Journal of experimental medicine.

[13]  Y. Goltsev,et al.  CASH, a Novel Caspase Homologue with Death Effector Domains* , 1997, The Journal of Biological Chemistry.

[14]  S. Srinivasula,et al.  FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[15]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[16]  G. Camussi,et al.  Development of Inflammatory Angiogenesis by Local Stimulation of Fas In Vivo , 1997, The Journal of experimental medicine.

[17]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Goeddel,et al.  Casper is a FADD- and caspase-related inducer of apoptosis. , 1997, Immunity.

[19]  Jürgen Bajorath,et al.  Identification of Amino Acid Residues Important for Ligand Binding to Fas , 1997, The Journal of experimental medicine.

[20]  T. Mosmann,et al.  Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity , 1997, European journal of immunology.

[21]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[22]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[23]  K. Sullivan,et al.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.

[24]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[25]  K. Okumura,et al.  Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis. , 1996, Biochemical and biophysical research communications.

[26]  M. Tanaka,et al.  Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. , 1996, Journal of immunology.

[27]  A. Hayday,et al.  A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice , 1996, The Journal of experimental medicine.

[28]  P. Schur,et al.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.

[29]  G. M. Fischer,et al.  Intracellular signaling for inducible antigen receptor-mediated Fas resistance in B cells. , 1996, Journal of immunology.

[30]  P. Kiener,et al.  Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils , 1996, The Journal of experimental medicine.

[31]  Y. S. Choi,et al.  Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. , 1996, Journal of immunology.

[32]  R. Eisenberg,et al.  bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. , 1995, Journal of immunology.

[33]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[34]  J. Banchereau,et al.  Fas ligation induces apoptosis of CD40-activated human B lymphocytes , 1995, The Journal of experimental medicine.

[35]  S. Targan,et al.  Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. , 1995, Journal of immunology.

[36]  P. Krammer,et al.  CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway , 1995, The Journal of experimental medicine.

[37]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[38]  S. Fortune,et al.  Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. , 1995, Journal of immunology.

[39]  W. Stohl,et al.  Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg). Regulatory role for SAg-dependent B cell cytolysis. , 1995, Journal of immunology.

[40]  Mark M. Davis,et al.  CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells , 1995, Nature.

[41]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[42]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[43]  B. Aggarwal,et al.  Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor , 1995, FEBS letters.

[44]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[45]  S. Ju,et al.  Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells , 1995, Nature.

[46]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[47]  P. Linsley,et al.  Human T cell-dependent B cell differentiation induced by staphylococcal superantigens. , 1994, Journal of immunology.

[48]  P. Krammer,et al.  Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. , 1994, Journal of immunology.

[49]  S. Ju,et al.  Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M R Alderson,et al.  The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. , 1994, Immunity.

[51]  L. Glimcher,et al.  Prevention of nephritis in major histocompatibility complex class II- deficient MRL-lpr mice , 1994, The Journal of experimental medicine.

[52]  F. Ramsdell,et al.  gld/gld mice are unable to express a functional ligand for Fas , 1994, European journal of immunology.

[53]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[54]  G. Klaus,et al.  Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. , 1994, Journal of immunology.

[55]  G. Inghirami,et al.  T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. , 1994, Journal of immunology.

[56]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[57]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[58]  I. Maclennan,et al.  Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl‐2 induction , 1993, European journal of immunology.

[59]  J. Mountz,et al.  Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene , 1993, The Journal of experimental medicine.

[60]  Jing Wu,et al.  B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40 , 1993, Nature.

[61]  K. Elkon,et al.  The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn , 1993, The Journal of experimental medicine.

[62]  S. Nagata,et al.  Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[63]  I. Stamenkovic,et al.  The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.

[64]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[65]  N. Chiorazzi,et al.  Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. , 1987, Journal of immunology.

[66]  J. Gray,et al.  Studies on human blood lymphocytes with iC3b (type 3) complement receptors. II. Characterization of subsets which regulate pokeweed mitogen-induced lymphocyte proliferation and immunoglobulin synthesis. , 1987, Clinical and experimental immunology.

[67]  A. Coutinho,et al.  A plaque assay for all cells secreting Ig of a given type or class , 1976, European journal of immunology.

[68]  B. Nickoloff,et al.  Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L). , 1998, The Journal of clinical investigation.

[69]  R. Eisenberg,et al.  Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. , 1991, Annual review of immunology.